Greedy Pharmaceutical Companies Fuel Disease Outbreaks, Doctors Without Borders Argues

Recent outbreaks of Hantavirus and Ebola, dominating global headlines, serve as stark reminders of the world's vulnerability to infectious diseases. Jon Gunnarsson Ruthman of Doctors Without Borders in Sweden emphasizes that for 50 years, his organization has witnessed the devastating toll of a flawed pharmaceutical system. This system first impacts people in impoverished countries, but as viruses know no borders, the consequences are ultimately global.

“

For 50 years, my organization has witnessed the deadly costs that the pharmaceutical system exacts. It first affects people in poor countries, but viruses do not respect borders.

Ruthman argues that the current global health crisis is being exacerbated on multiple fronts. Record-high mortality from healthcare attacks, drastic cuts in aid, and detrimental policy shifts are weakening international disease surveillance systems. This environment creates fertile ground for infectious diseases to spread rapidly, with the most vulnerable bearing the brunt of the impact.

“

The global health crisis creates fertile ground for infectious diseases to spread faster, and as is often the case, the most vulnerable are hit hardest.

The World Health Organization estimates that two billion people lack regular access to essential medicines. This is often not due to technical or scientific limitations, but rather deliberate political and economic choices. Many new innovations are priced prohibitively high, protected by long patents that prevent the production of cheaper generic versions, and are only made available to select countries.

“

Many new innovations are sold at high prices, with long patents that prevent cheaper versions from being produced, and only to select countries.

At the recent WHO annual meeting in Geneva, the management of disease outbreaks was a top agenda item. However, member states failed to agree on the proposed "pabs addendum" to the WHO's pandemic treaty. This addendum aims to address the inequity where countries contributing samples, data, and participation in medical research often do not receive access to the resulting vaccines, medicines, and tests. The unequal global distribution of COVID-19 vaccines serves as a prime example. The decision is now postponed, potentially until 2027, jeopardizing the entire pandemic treaty's implementation.

“

The unequal global access to COVID-19 vaccines is one of many examples of this.